argenx

target reach ladder climb meet win beat competition

Biotech

J&J's phase 2 Sjögren's data support FcRn strategy

Patients who received the 15-mg/kg dose demonstrated a more than 70% improvement in the primary endpoint of a measure of organ disease severity.

James Waldron Jun 17, 2024 8:47am

graphic image of a cube with an arrow nailing the bullseye

Roivant FcRn inhibitor avoids cholesterol problem, shares spike

Sep 26, 2023 10:56am

A business window with a sign that says welcome we are open

Metrodora opens neuroimmune research center in Salt Lake City

Apr 19, 2023 11:11am

business deal strategy partnership gears plan

Argenx, Genmab join forces to expand into new therapeutic areas

Apr 17, 2023 6:20am

UCB races to regulators after $2B rare disease bet delivers data

Feb 4, 2022 8:25am

Janssen building

Johnson & Johnson culls $1.6B argenx blood cancer drug collab

Jun 7, 2021 4:14am